...
首页> 外文期刊>The American Journal of the Medical Sciences >Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.
【24h】

Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.

机译:血液透析患者使用帕米膦酸保守治疗伴发三甲亢进的高钙血症。

获取原文
获取原文并翻译 | 示例
           

摘要

Secondary hyperparathyroidism and the associated metabolic abnormalities are common complications of chronic kidney disease. When these disorders cannot be managed by conventional measures, including phosphate restriction, phosphate binders, vitamin D therapy, and calcimimetics, tertiary hyperparathyroidism and the associated metabolic abnormalities may develop. In such cases parathyroidectomy is required. We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate. This patient had failed conventional measures to manage hypercalcemia and presented with mental status changes. Pamidronate therapy was associated with a sustained decrease in serum calcium concentration and improvement in clinical symptoms. This is the first case, to our knowledge, in which pamidronate was used in a patient refractory to all other reasonable medical management, including calcimimetics.
机译:继发性甲状旁腺功能亢进症和相关的代谢异常是慢性肾脏疾病的常见并发症。当这些疾病无法通过常规措施(包括磷酸盐限制剂,磷酸盐结合剂,维生素D治疗和拟钙剂)来控制时,可能会发展为第三甲状旁腺功能亢进症和相关的代谢异常。在这种情况下,需要进行甲状旁腺切除术。我们报告了一个病例,其中非手术候选人的三级甲状旁腺功能亢进和难治性高钙血症患者接受了双膦酸盐帕米膦酸盐治疗。该患者未能通过常规措施控制高钙血症,并出现精神状态改变。帕米膦酸治疗与血清钙浓度持续降低和临床症状改善有关。据我们所知,这是第一种情况,其中帕米膦酸用于耐所有其他合理药物治疗(包括拟钙剂)的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号